GlassScriptPhysician profile
Michael P Esposito
NPI 1154390458
$28,018.10
in general payments reported to CMS, 2019-2025
31 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $160 · 2021: $884 · 2022: $383 · 2023: $129 · 2024: $14K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Food and Beverage: $1,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,710.00 |
| Food and Beverage | $1,236.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $25,641.52 | 2021-2025 | Aquabeam System, Aquabeam Robotic System |
| Intuitive Surgical, INC. | $272.45 | 2019 | |
| Ethicon US, LLC | $271.00 | 2024-2025 | Stratafix, Surgicel Nu-Knit, Echelon Flex |
| Astellas Pharma US INC | $228.62 | 2019-2022 | |
| Vertos Medical, INC. | $226.71 | 2021 | |
| Boston Scientific Corporation | $204.33 | 2019-2022 | |
| Kerecis Limited | $155.32 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Bayer Healthcare Pharmaceuticals INC. | $146.82 | 2019-2025 | |
| Urogen Pharma, INC. | $99.99 | 2021-2022 | |
| Coloplast Corp | $89.11 | 2022 | |
| Myovant Sciences INC. | $65.19 | 2021-2022 | |
| Biotissue Holdings INC. | $64.28 | 2019 | |
| Tolmar, INC. | $60.86 | 2024 | |
| Allergan, INC. | $57.59 | 2019-2021 | |
| Pfizer INC. | $53.54 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $51.38 | 2024 | Channel Drain |
| Abbott Laboratories | $49.47 | 2021 | |
| Calyxo, INC. | $45.08 | 2023 | Cvac Aspiration System |
| Dendreon Pharmaceuticals LLC | $42.86 | 2019-2025 | Provenge |
| Mimedx Group, INC. | $25.26 | 2025 | |
| Metuchen Pharmaceuticals | $22.68 | 2019-2020 | |
| Seapearl East, INC | $22.06 | 2023 | |
| Olympus America INC. | $19.21 | 2022 | |
| Axonics, INC. | $18.60 | 2022 | |
| Endo USA, INC. | $18.50 | 2025 | Aveed, Xiaflex |
| Urovant Sciences INC | $14.93 | 2021 | |
| Endo Pharmaceuticals INC. | $14.88 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $14.57 | 2021 | |
| Janssen Biotech, INC. | $12.23 | 2019 | |
| Amniox Medical, INC. | $9.06 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$200,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Esposito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.